University of Miami's Miller School of Medicine and Miami Cardiovascular Innovations Partner to Create Biologically Engineered Stents

Share Article

Miami Cardiovascular Innovations is pleased to announce an agreement to collaborate in research efforts in the development of biologically engineered medical devices, including coronary stents to overcome late stent thrombosis, pacing leads and other products in the cardiovascular space, with University of Miami's Miller School of Medicine.

Miami Cardiovascular Innovations is pleased to announce an agreement to collaborate in research efforts in the development of biologically engineered medical devices, including coronary stents to overcome late stent thrombosis, pacing leads and other products in the cardiovascular space, with University of Miami's Miller School of Medicine.

The biologically engineered stent -- or BES stent now under development -- for which the company has filed patents and the trademark Progeny, can be implanted via minimally invasive procedure. The agreement will use Miami Cardiovascular's novel stem cell-based stent design and the University of Miami's research laboratories and staff to conduct testing. Miami Cardiovascular's biologically engineered approach to stenting can lead to other procedures that could extend and improve the lives of patients requiring different stents.

"I am delighted to have such a prestigious partner in developing this new, ground-breaking medical device technology," said Frank Avellanet, President & CEO of Miami Cardiovascular. "Our know-how combined with the Miller School of Medicine's expertise will ensure the successful outcome of our collaboration and will allow us to quickly bring this new life-saving device to market."

Miami Cardiovascular is seeking additional investors to continue its research and development for several applications. Among the first devices that we are focusing our development work are the next generation of coronary and peripheral stents. Combined these markets exceed $5 billion in annual sales in the US and abroad.

"This unique opportunity brings The University of Miami and Miami Cardiovascular Innovations together with engineers and scientists to develop clinically useful medical products, including biologically engineered stents. This type of collaboration underscores our commitment to developing new devices and bringing the best new technologies to our patients" said Bart Chernow, M.D., Vice President for Special Programs & Resource Strategy for the University.

About Miami Cardiovascular Innovations
Miami Cardiovascular Innovations is an interdisciplinary company that combines clinical medicine, molecular biology and biomedical engineering. The three sciences are combined to develop biologically engineered devices. Typically devices are products made out of plastic, metal or a combination of both materials. But MCI uses a more sophisticated approach where it adds science to devices - in this case using stem cells to attract endothelial cells.

For More Information Contact:     
Frank Avellanet
President & CEO
Direct: 305-243-4840
Email: MiamiCardio @ aol.com

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Frank Avellanet
Miami Cardiovascular Innovations
914-441-7119
Email >

Frank Avellanet
Miami Cardiovascular Innovations
305-243-4840
Email >